Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
Healthcare
$0.31 -0.58%
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
52W Low $0.53High $2.35
Volume 2.77M
Average 3.79M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$68.26M
FY 2025 · Annual
Investing Cash Flow
$56.08M
FY 2025 · Annual
+4858.7% YoYFinancing Cash Flow
$108.41M
FY 2025 · Annual
+127.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Depreciation & Amortization | 2.96M | 6.47M | 8.69M | 8.47M | 8.85M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.95M | 11.47M | 15.31M | 16.5M | 13.05M |
| Change in Working Capital | 4.74M | (849K) | (5.65M) | (7.93M) | (2.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.6M | 1.66M | (3.28M) | (581K) | (1.43M) |
| Other Working Capital | (3.86M) | (2.51M) | (2.37M) | (7.35M) | (1.03M) |
| Other Non-Cash Items | 1.26M | 2.16M | 3.66M | 3.59M | 2.9M |
| Operating Cash Flow | (60.81M) | (104.42M) | (102.07M) | (90.5M) | (68.26M) |
| Capital Expenditures | (25.12M) | (20.63M) | (1.24M) | (1.03M) | (618K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (213.44M) | (140.48M) | (56.64M) | (87.07M) | 0 |
| Sales of Investments | 0 | 244.75M | 106.62M | 89.21M | 56.7M |
| Other Investing Activities | 0 | 8K | (25K) | 17K | 0 |
| Investing Cash Flow | (238.56M) | 83.65M | 48.72M | 1.13M | 56.08M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.54M | 77.39M | 3.87M | 46.76M | 108.41M |
| Common Stock Repurchased | (13K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 461K | 380K | 181K | 987K | 0 |
| Financing Cash Flow | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.41M) | 57M | (49.31M) | (41.62M) | 96.22M |
| Free Cash Flow | (85.93M) | (125.05M) | (103.31M) | (91.53M) | (68.88M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$90.6M
+ D&A$8.8M
+ Stock-Based Comp$13.0M
+ Deferred Tax$0
- Working Capital-$2.5M
+ Other Non-Cash$2.9M
= Operating Cash Flow-$68.3M
- Capex-$618.0K
= Free Cash Flow-$68.9M
Analysis
FY2025 free cash flow is -$68.9M. FCF conversion is 76.0% of net income. Operating cash flow was -$68.3M, with capex of -$618.0K. The largest bridge item is Stock-Based Comp at $13.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| DEF 14A | DEF 14A filing | Oct 23, 2026 | |
| DEFA14A | DEFA14A filing | Oct 23, 2026 | |
| PRE 14A | PRE 14A filing | Oct 13, 2026 |
Does TNYA generate free cash flow?
Tenaya Therapeutics, Inc. (TNYA) generated -$68.88M of free cash flow in fiscal 2025.
How much operating cash flow does TNYA produce?
Operating cash flow was -$68.26M, before capital expenditures of $618,000.00.
Continue the stock analysis
Jump to another research area for this company.